Outset Medical (OM) News Today

Mubadala Investment Co PJSC bought a new position in Outset Medical, Inc. (NASDAQ:OM - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 1,440,601 shares of the company's stock, valued at approximately $7,794,000. Outset M

GSA Capital Partners LLP lifted its position in shares of Outset Medical, Inc. (NASDAQ:OM - Free Report) by 508.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 514,317 shares of the company's stock

Bellevue Group AG lowered its position in Outset Medical, Inc. (NASDAQ:OM - Free Report) by 26.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,760,134 shares of the company's stock after selling 648,296

Outset Medical, Inc. (NASDAQ:OM - Get Free Report) Director D Keith Grossman sold 38,117 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $3.78, for a total transaction of $144,082.26. Following the transaction, the director now owns 47,805 shares in the company, valued at $180,702.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Outset Medical, Inc. (NASDAQ:OM - Get Free Report) CTO Jean-Olivier Racine sold 8,306 shares of the business's stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $3.27, for a total value of $27,160.62. Following the transaction, the chief technology officer now directly owns 265,325 shares in the company, valued at $867,612.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Outset Medical (NASDAQ:OM) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=586754)

BTIG Research initiated coverage on Outset Medical in a research note on Monday. They issued a "buy" rating and a $6.00 price objective on the stock.

CL King upgraded Outset Medical from a "neutral" rating to a "buy" rating and set a $6.00 target price on the stock in a research note on Friday.

Braidwell LP grew its holdings in Outset Medical, Inc. (NASDAQ:OM - Free Report) by 64.4% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 2,400,427 shares of the company's stock after buying an additional 940,059 shares during the period. Braidwell LP owne

Outset Medical, Inc. (NASDAQ:OM - Get Free Report) General Counsel John L. Brottem sold 3,341 shares of the firm's stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $3.57, for a total transaction of $11,927.37. Following the sale, the general counsel now owns 245,046 shares in the company, valued at approximately $874,814.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.